Trial results

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804 on ClinicalTrials.gov · last registry update 2026-05-08

Closed to new participants; the 140 already enrolled are still being followed. Due to report September 2026, alongside 37 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Renal Sinus Fat Content (MRI). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 8 February 2023 — 3 years so far. tirzepatide is approved in the US, but not for chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

140

Started

2023-02-08

Primary completion

2026-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change from Baseline in Renal Sinus Fat Content (MRI)

Conditions studied

Overweight · Obesity · Chronic Kidney Disease · Type 2 Diabetes · T2D

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.